Andrew Obenshain is Head of Europe at bluebird bio, a biotech company focused on developing potentially transformative cell & gene therapies for severe genetic and rare diseases.
Before taking up this role in 2016, he was at Shire in Paris, France where he was the general manager of France and Benelux overseeing a portfolio including seven rare disease products. Prior to Shire, Andrew spent eight years at Genzyme and Sanofi holding roles of increasing responsibility in business development, marketing and global commercial operations.
Mr. Obenshain received his MBA from Northwestern University’s Kellogg School of Management, and his B.A. in genetics, cell and developmental biology from Dartmouth College.
The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.